Mr Hao-Wen Sim

Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E, 2021, 'Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer', Oncology (Switzerland), vol. 99, pp. 49 - 56, http://dx.doi.org/10.1159/000510446

Hecht JR; Lonardi S; Bendell J; Sim HW; Macarulla T; Lopez CD; Van Cutsem E; Muñoz Martin AJ; Park JO; Greil R; Wang H; Hozak RR; Gueorguieva I; Lin Y; Rao S; Ryoo BY, 2021, 'Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, pp. 1108 - 1118, http://dx.doi.org/10.1200/JCO.20.02232

Kong BY; Carter C; Nowak AK; Hovey E; Lwin Z; Haghighi N; Gan HK; Sim HW; Ziegler DS; Barton K; Parkinson J; Leonard R; Khasraw M; Foote M, 2021, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13606

Floros P; Rao A; McCloy RA; Sim HW; Chin VT; Leavers BC; Crawford JA; Gallagher RM, 2021, 'Altered presentation of oropharyngeal cancer, a 6-year review', ANZ Journal of Surgery, vol. 91, pp. 1240 - 1245, http://dx.doi.org/10.1111/ans.16537

Feng S; Sim H-W; Bucur R; Aggarwal R; Abreu P; Ray M; Herman M; Cheng D; Chen Z; Zhang W; Greig PD; Wei AC-C; Moulton C-A; McGilvray IM; Cleary SP; Gallinger S; Sapisochin G; Knox JJ; Liu G; Chen EX, 2020, 'Preoperative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC).', Journal of Clinical Oncology, vol. 38, pp. 571 - 571, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.571

Hecht JR; Lonardi S; Bendell JC; Sim H-W; Macarulla T; Lopez CD; Van Cutsem E; Martin AJM; Park JO; Greil R; Lin Y; Rao S; Ryoo B-Y, 2020, 'Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).', Journal of Clinical Oncology, vol. 38, pp. 637 - 637, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.637

Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC, 2020, 'Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European urology oncology, vol. 3, pp. 530 - 539, http://dx.doi.org/10.1016/j.euo.2020.01.001

Hallal S; Azimi A; Wei H; Ho N; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL, 2020, 'A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: A new avenue for glioma tumour surveillance', International Journal of Molecular Sciences, vol. 21, pp. 1 - 26, http://dx.doi.org/10.3390/ijms21134754

Alghamdi MA; Amaro CP; Lee-Ying R; Sim HW; Samwi H; Chan KK; Knox JJ; Ko YJ; Swiha M; Batuyong E; Romagnino A; Cheung WY; Tam VC, 2020, 'Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database', Cancer Medicine, vol. 9, pp. 4918 - 4928, http://dx.doi.org/10.1002/cam4.3228

Hallal S; Khani SE; Wei H; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL, 2020, 'Deep sequencing of small RNAs from neurosurgical extracellular vesicles substantiates miR-486-3p as a circulating biomarker that distinguishes glioblastoma from lower-grade astrocytoma patients', International Journal of Molecular Sciences, vol. 21, pp. 1 - 22, http://dx.doi.org/10.3390/ijms21144954

Lamb LS; Sim HW; McCormack AI, 2020, 'Exploring the role of novel medical therapies for aggressive pituitary tumors: A review of the literature—“are we there yet?”', Cancers, vol. 12, http://dx.doi.org/10.3390/cancers12020308

Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R, 2020, 'Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab', Cancer Medicine, vol. 9, pp. 4640 - 4647, http://dx.doi.org/10.1002/cam4.3116

Ma LX; Espin-Garcia O; Lim CH; Jiang DM; Sim HW; Natori A; Chan BA; Suzuki C; Chen EX; Liu G; Brar SS; Swallow CJ; Yeung JC; Darling GE; Wong RK; Kalimuthu SN; Conner J; Elimova E; Jang RW, 2020, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers', Journal of Gastrointestinal Oncology, vol. 11, pp. 356 - 365, http://dx.doi.org/10.21037/jgo.2020.03.03

Ma LX; Sun P; Espin-Garcia O; Suzuki C; Jiang DM; Lim CH; Taylor K; Chan BA; Sim H-W; Natori A; Chen EX; Liu G; Knox JJ; Yeung J; Darling GE; Kim J; Kalimuthu S; Elimova E; Jang RW-J, 2020, 'Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.', Journal of Clinical Oncology, vol. 38, pp. 328 - 328, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.328

Sim HW; Nowak AK; Lwin Z; Khasraw M, 2021, 'Management of glioblastoma: An Australian perspective', Chinese Clinical Oncology, vol. 10, http://dx.doi.org/10.21037/cco.2020.02.05

Agar M; Nowak A; Hovey E; Barnes E; Simes J; Vardy J; Wheeler H; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim H-W; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh E-S, 2020, 'QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE', Neuro-Oncology, vol. 22, pp. ii179 - ii180, http://dx.doi.org/10.1093/neuonc/noaa215.748

Lamb LS; Sim HW; McCormack AI, 2020, 'Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy', Frontiers in Endocrinology, vol. 11, http://dx.doi.org/10.3389/fendo.2020.576027

Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim HW; Natori A; Chan BA; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW; Elimova E, 2020, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma', Cancer Medicine, vol. 9, pp. 3023 - 3032, http://dx.doi.org/10.1002/cam4.2948

Taylor K; Espin-Garcia O; Jiang DM; Yokom D; Ma LX; Lim CH; Chan BA; Sun P; Sim H-W; Natori A; Liu G; Darling GE; Wong R; Chen EX; Jang RW-J; Veit-Haibach P; Rozenberg D; Elimova E, 2019, 'Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.', Journal of Clinical Oncology, vol. 37, pp. 171 - 171, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.171

Fung AS; Tam VC; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Lee-Ying RM, 2019, 'Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).', Journal of Clinical Oncology, vol. 37, pp. 422 - 422, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.422

Khasraw M; Leanne McDonald K; Rosenthal M; Lwin Z; Ashley D; Wheeler H; Barnes E; Foote M; Koh E-S; Sulman E; Back M; Buckland M; Sim H-W; Fisher L; Leonard R; Hall M; Yip S; Simes J, 2019, 'ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY', Neuro-Oncology, vol. 21, pp. vi18 - vi18, http://dx.doi.org/10.1093/neuonc/noz175.067

Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2019, 'Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase mutations in gliomas', Clinical Cancer Research, vol. 25, pp. 3366 - 3373, http://dx.doi.org/10.1158/1078-0432.CCR-18-3205

Kroeger N; Li H; De Velasco G; Donskov F; Sim H-W; Stuehler V; Wells JC; Stukalin I; Heide J; Bedke J; Agarwal N; Parekh H; Rini B; Knox EJ; Pantuck A; Choueiri TK; Heng DYC, 2019, 'Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies', CLINICAL GENITOURINARY CANCER, vol. 17, pp. 65 - 71, http://dx.doi.org/10.1016/j.clgc.2018.09.006

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', Journal of Clinical Oncology, vol. 37, pp. 4069 - 4069, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4069

Herman M; Zhang Y; Wang L; Sim H-W; Knox JJ, 2019, 'Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.', JOURNAL OF CLINICAL ONCOLOGY, vol. 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e15645

Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', Journal of Clinical Oncology, vol. 37, pp. e15579 - e15579, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15579

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', Journal of Clinical Oncology, vol. 37, pp. 164 - 164, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.164

Jiang DM; Suzuki C; Espin-Garcia O; Pintilie M; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', Journal of Clinical Oncology, vol. 37, pp. 162 - 162, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.162

Fung AS; Lee-Ying RM; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Tam VC, 2019, 'Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.', Journal of Clinical Oncology, vol. 37, pp. 438 - 438, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.438

Doherty M; Tam VC; McNamara MG; Hedley DW; Dhani NC; Chen EX; Jang RW-J; Tang PA; Sim H-W; O'Kane GM; DeLuca S; Wang L; Brooks K; Knox JJ, 2018, 'Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.', Journal of Clinical Oncology, vol. 36, pp. 4084 - 4084, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4084

Stukalin I; Connor Wells J; Fraccon A; Pasini F; Porta C; Lalani AKA; Srinivas S; Alex Bowman I; Brugarolas J; Lee JL; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim HW; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2018, 'Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)', Kidney Cancer, vol. 2, pp. 31 - 36, http://dx.doi.org/10.3233/KCA-170020

Natori A; Chan BA; Sim HW; Ma L; Yokom DW; Chen E; Liu G; Darling G; Swallow C; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox J; Elimova E; Jang RW, 2018, 'Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer', Current Oncology, vol. 25, pp. 366 - 370, http://dx.doi.org/10.3747/co.25.4208

Mitchell L; Tam S; Lewin J; Srikanthan A; Heck C; Hodgson D; Vakeesan B; Sim HW; Gupta A, 2018, 'Measuring the impact of an adolescent and young adult program on addressing patient care needs', Journal of Adolescent and Young Adult Oncology, vol. 7, pp. 612 - 617, http://dx.doi.org/10.1089/jayao.2018.0015

Samawi HH; Sim HW; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko YJ; Davies JM; Lim HJ; Cheung WY; Tam VC, 2018, 'Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database', Cancer Medicine, vol. 7, pp. 2816 - 2825, http://dx.doi.org/10.1002/cam4.1493

Sim HW; Knox J, 2018, 'Hepatocellular carcinoma in the era of immunotherapy', Current Problems in Cancer, vol. 42, pp. 40 - 48, http://dx.doi.org/10.1016/j.currproblcancer.2017.10.007

Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2018, 'Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', Cancer, vol. 124, pp. 3677 - 3683, http://dx.doi.org/10.1002/cncr.31595

Sim HW; Morgan ER; Mason WP, 2018, 'Contemporary management of high-grade gliomas', CNS oncology, vol. 7, pp. 51 - 65, http://dx.doi.org/10.2217/cns-2017-0026

Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA, 2018, 'Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma', International Journal of Cancer, vol. 142, pp. 57 - 65, http://dx.doi.org/10.1002/ijc.31039

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang M; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. 122 - 122, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.122

Yokom D; Natori A; Sim H-W; Chan BA; Moignard S; Sun P; Lim CH; Jiang DM; Ma LX; Darling GE; Swallow CJ; Brierley JD; Wong R; Liu G; Chen EX; Knox JJ; Alibhai SMH; Jang RW-J; Elimova E, 2018, 'Management of metastatic gastric and esophageal cancer in older adults.', Journal of Clinical Oncology, vol. 36, pp. 163 - 163, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.163

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. 131 - 131, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.131

Jiang DM; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Knox JJ; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Jang RW-J; Elimova E, 2018, 'Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).', Journal of Clinical Oncology, vol. 36, pp. 147 - 147, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.147

Ma LX; Lim CH; Sun P; Jiang M; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Le LW; Chen EX; Liu G; Swallow CJ; Darling GE; Kongkham PN; Shultz D; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer.', Journal of Clinical Oncology, vol. 36, pp. 145 - 145, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.145

Chan BA; Sim H-W; Natori A; Moignard S; Yokom D; Lim CH; Jiang DM; Chen EX; Knox JJ; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Hafezi-Bakhtiari S; Elimova E; Jang RW-J, 2018, 'Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.', Journal of Clinical Oncology, vol. 36, pp. 148 - 148, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.148

O'Kane GM; Fraser A; Moignard S; Dodd A; Creighton S; Sim H-W; Aung KL; Borgida A; Gallinger S; Knox JJ, 2018, 'The impact of lung and bone metastases on prognosis in advanced PDAC.', Journal of Clinical Oncology, vol. 36, pp. 494 - 494, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.494

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang DM; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. 4066 - 4066, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4066

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2 positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. e16069 - e16069, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e16069

Sim H-W; Stundzia A; Pierre S; Metser U; O’Malley M; Elimova E; Sridhar SS; Hansen A, 2018, 'Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)', Annals of Oncology, vol. 29, pp. viii318 - viii318, http://dx.doi.org/10.1093/annonc/mdy283.105

Meyers DE; Lee-Ying R; Alghamdi M; Sim H-W; Zaborska VO; Ko Y-J; Raycraft T; Batuyong E; Cheung WY; Samawi H; Davies JM; Tam VC, 2018, 'Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database', Annals of Oncology, vol. 29, pp. viii238 - viii238, http://dx.doi.org/10.1093/annonc/mdy282.089

Nejad R; Nassiri F; Mamatjan Y; Sim H-W; Chen E; Agnihotri S; Aldape K; Zadeh G, 2018, 'CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS', Neuro-Oncology, vol. 20, pp. vi33 - vi33, http://dx.doi.org/10.1093/neuonc/noy148.125

Yip SM; Ruiz Morales JM; Donskov F; Fraccon A; Basso U; Rini BI; Lee JL; Bjarnason GA; Sim HW; Beuselinck B; Kanesvaran R; Brugarolas J; Koutsoukos K; Fu SYF; Yuasa T; Davis I; Alva A; Kollmannsberger C; Choueiri TK; Heng DYC, 2017, 'Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)', Kidney Cancer, vol. 1, pp. 41 - 47, http://dx.doi.org/10.3233/KCA-160002

Sim H-W; Nejad R; Zhang W; Mason WP; Bernstein M; Aldape K; Zadeh G; Chen EX, 2017, 'Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas.', Journal of Clinical Oncology, vol. 35, pp. 2037 - 2037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2037

Basappa NS; Lalani A-KA; Li H; Kalirai A; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; Levesque E; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, vol. 35, pp. 468 - 468, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.468

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Soulieres D; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.', Journal of Clinical Oncology, vol. 35, pp. 492 - 492, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.492

Stukalin I; Wells C; Fraccon AP; Pasini F; Porta C; Moreira RB; Srinivas S; Bowman IA; Brugarolas J; Lee J-L; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim H-W; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2017, 'Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).', Journal of Clinical Oncology, vol. 35, pp. 498 - 498, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.498

Lalani AKA; Li H; Heng DYC; Wood L; Kalirai A; Bjarnason GA; Sim HW; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa NS, 2017, 'First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience', Journal of the Canadian Urological Association, vol. 11, pp. 112 - 117, http://dx.doi.org/10.5489/cuaj.4398

Sim HW; Knox J; Dawson LA, 2017, 'An Update on Randomized Clinical Trials in Hepatocellular Carcinoma', Surgical Oncology Clinics of North America, vol. 26, pp. 647 - 666, http://dx.doi.org/10.1016/j.soc.2017.05.006

Sim H-W; Chan BA; Natori A; Lim CH; Jiang DM; Moignard S; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.', Journal of Clinical Oncology, vol. 35, pp. 4053 - 4053, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4053

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, vol. 35, pp. 699 - 699, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.699

Sim H-W; Chan B; Natori A; Lim CH; Jiang DM; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 35, pp. 126 - 126, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.126

Natori A; Chan B; Sim H-W; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J-HJ; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 35, pp. 189 - 189, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.189

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, vol. 35, pp. 3600 - 3600, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3600

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).', Journal of Clinical Oncology, vol. 35, pp. 4580 - 4580, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4580

Bosse D; Xie W; Wells C; Lalani A-KA; Donskov F; Bent A; Sim H-W; Beuselinck B; Bamias A; Porta C; Vaishampayan UN; Pal SK; Agarwal N; Srinivas S; Rini BI; Alva AS; Wood L; Kapoor A; Choueiri TK; Heng DYC, 2017, 'Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).', Journal of Clinical Oncology, vol. 35, pp. e16065 - e16065, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16065

Samawi H; Sim H-W; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko Y-J; Cheung WY; Tam VC, 2017, 'Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database.', Journal of Clinical Oncology, vol. 35, pp. e15653 - e15653, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15653

Alghamdi MA; Lee-Ying R; Sim H-W; Samawi H; Knox JJ; Romagnino A; Ko Y-J; Chan KK; Swiha M; Batuyong E; Cheung WY; Tam VC, 2017, 'Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.', Journal of Clinical Oncology, vol. 35, pp. 4084 - 4084, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4084

Basappa NS; Lalani A-KA; Kalirai A; Li H; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, vol. 35, pp. e16078 - e16078, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16078

Natori A; Chan BA; Sim H-W; Ma LX; Yokom D; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 35, pp. 10037 - 10037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10037

Donskov F; Xie W; Wells JC; Fraccon AP; Pasini F; Porta C; Stukalin I; Lee JL; Bamias A; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim H-W; Agarwal N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC, 2017, 'Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy', Annals of Oncology, vol. 28, pp. v311 - v312, http://dx.doi.org/10.1093/annonc/mdx371.037

Nejad R; Sim H; Aldape K; Mason W; Bernstein M; Gentili F; Kalia S; Tung T; Chen E; Zadeh G, 2017, 'P10.21 2-hydroxyglutarate as a biomarker for IDH mutation in low grade gliomas', Neuro-Oncology, vol. 19, pp. iii89 - iii90, http://dx.doi.org/10.1093/neuonc/nox036.339

Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European Journal of Cancer, vol. 65, pp. 102 - 108, http://dx.doi.org/10.1016/j.ejca.2016.06.016

Chan B; Sim H-W; Zimmermann C; Krzyzanowska MK, 2016, 'Systematic review of interventions to facilitate advance care planning (ACP) in cancer patients.', Journal of Clinical Oncology, vol. 34, pp. 21 - 21, http://dx.doi.org/10.1200/jco.2016.34.26_suppl.21

Li H; Kroeger N; de Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh HD; Rini BI; Knox JJ; Pantuck AJ; Choueiri TK; Heng DYC, 2016, 'The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.', Journal of Clinical Oncology, vol. 34, pp. 552 - 552, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.552

Kröger N; Li H; De Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh H; Rini B; Knox J; Pantuck A; Choueiri T; Heng D, 2016, '756 Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies', European Urology Supplements, vol. 15, pp. e756 - e756, http://dx.doi.org/10.1016/s1569-9056(16)60758-3

Sim H-W; Zadeh G; Mason WP; Aldape K; Bernstein M; Gentili F; Hodaie M; Kalia S; Kongkham PN; Zhang W; Tung T; Chen EX, 2016, 'Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues.', Journal of Clinical Oncology, vol. 34, pp. 2028 - 2028, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.2028

Ruiz Morales JM; Swierkowski M; Wells C; Fraccon AP; La Russa F; Donskov F; Bjarnason GA; Lee J-L; Sim H-W; Beuselinck B; Wood L; Yuasa T; Pezaro CJ; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).', Journal of Clinical Oncology, vol. 34, pp. 4510 - 4510, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4510

Lalani A-K; Li H; Heng D; Wood L; Kalirai A; Bjarnason G; Sim H-W; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa N, 2016, 'Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience', Annals of Oncology, vol. 27, pp. vi285 - vi285, http://dx.doi.org/10.1093/annonc/mdw373.46

Tan LTY; Lewin JH; Urban D; Sim H-W; Hicks RJ; Byron K; Guccione L; Schaef E; Luen SJ; Tothill R; Schofield P; Bowtell D; Mileshkin LR, 2015, 'Retrospective review of the impact of a dedicated Cancer of Unknown Primary (CUP) clinic.', Journal of Clinical Oncology, vol. 33, pp. e17680 - e17680, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e17680

Sim HW; Morris PG; Patil S; Khasraw M, 2014, 'Brain metastases in breast cancer', Expert Review of Anticancer Therapy, vol. 14, pp. 173 - 183, http://dx.doi.org/10.1586/14737140.2014.863468

Malone ER; Sim HW; Stundzia A; Pierre S; Metser U; O’Malley M; Sacher AG; Sridhar SS; Hansen AR, 2022, 'Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma', Canadian Urological Association Journal, vol. 16, http://dx.doi.org/10.5489/CUAJ.7467

Lim J; Akbar Ali S; Prawira A; Sim H-W, 2021, 'Impact of travel distance on outcomes for clinical trial patients - The Kinghorn Cancer Centre (TKCC) Experience.', Intern Med J, http://dx.doi.org/10.1111/imj.15561

Matsuyama M; Sachchithananthan M; Leonard R; Besser M; Nowak AK; Truran D; Vajdic CM; Zalcberg JR; Gan HK; Gedye C; Varikatt W; Koh E-S; Kichenadasse G; Sim H-W; Gottardo NG; Spyridopoulos D; Jeffree RL, 2021, 'What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry', Neuro-Oncology Practice, http://dx.doi.org/10.1093/nop/npab055

Sim H-W; Barnes E; Lwin Z; Rosenthal M; Wheeler H; Koh E-S; Foote MC; Fisher L; Leonard R; Hall M; Simes J; Khasraw M, 2019, 'Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2042

Khasraw M; McDonald KL; Rosenthal M; Lwin Z; Ashley DM; Wheeler H; Barnes E; Foote MC; Koh E-S; Sulman EP; Back M; Buckland M; Sim H-W; Fisher L; Leonard R; Hall M; Yip S; Simes J, 2019, 'A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2011

Sim HW; Mcdonald KL; Lwin Z; Barnes EH; Rosenthal M; Foote MC; Koh ES; Back M; Wheeler H; Sulman EP; Buckland ME; Fisher L; Leonard R; Hall M; Ashley DM; Yip S; Simes J; Khasraw M, 2021, 'A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: The VERTU study', in Neuro-Oncology, OXFORD UNIV PRESS INC, Phoenix, AZ, Vol. 23, pp. 1736 - 1749, presented at 24th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS, Phoenix, AZ, 20 November 2019 - 24 November 2019, http://dx.doi.org/10.1093/neuonc/noab111

Xu K; Lo A; Chin V; Gzell C; O'Connor C; Forstner D; Gallagher R; Bova R; Crawford J; Harvey R; Lochhead A; Earls P; Qiu MR; Hsu E; Bigg-Wither G; Chan L; Bao H; Foltyn P; Sim HW; Prawira A, 2018, 'Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)', in Annals of oncology : official journal of the European Society for Medical Oncology, OXFORD UNIV PRESS, Munich, GERMANY, pp. viii389, presented at 43rd ESMO Congress (ESMO), Munich, GERMANY, 19 October 2018 - 23 October 2018, http://dx.doi.org/10.1093/annonc/mdy287.049

Hallal S; Azimi A; Wei H; Ho N; Lee M; Sim H-W; Sy J; Shivalingam B; Buckland ME; Kaufman KL, A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: a new avenue for glioma tumour surveillance, http://dx.doi.org/10.1101/2020.03.05.979716

Malone ER; Sim HW; Stundzia A; Pierre S; Metser U; O’Malley M; Sacher AG; Sridhar SS; Hansen AR, 2022, 'Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma', Canadian Urological Association Journal, vol. 16, http://dx.doi.org/10.5489/CUAJ.7467

Field KM; Barnes EH; Sim HW; Nowak AK; Simes J; Rosenthal MA; Wheeler H; Hovey EJ; Cher LM, 2021, 'Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial', Journal of Clinical Neuroscience, vol. 94, pp. 321 - 327, http://dx.doi.org/10.1016/j.jocn.2021.10.022

Parmar A; Qazi AA; Stundzia A; Sim HW; Lewin J; Metser U; O'Malley M; Hansen AR, 2021, 'Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer', Canadian Urological Association Journal, vol. 16, http://dx.doi.org/10.5489/CUAJ.7294

Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E, 2021, 'Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer', Oncology (Switzerland), vol. 99, pp. 49 - 56, http://dx.doi.org/10.1159/000510446

Hecht JR; Lonardi S; Bendell J; Sim HW; Macarulla T; Lopez CD; Van Cutsem E; Muñoz Martin AJ; Park JO; Greil R; Wang H; Hozak RR; Gueorguieva I; Lin Y; Rao S; Ryoo BY, 2021, 'Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, pp. 1108 - 1118, http://dx.doi.org/10.1200/JCO.20.02232

Lim J; Akbar Ali S; Prawira A; Sim H-W, 2021, 'Impact of travel distance on outcomes for clinical trial patients - The Kinghorn Cancer Centre (TKCC) Experience.', Intern Med J, http://dx.doi.org/10.1111/imj.15561

Matsuyama M; Sachchithananthan M; Leonard R; Besser M; Nowak AK; Truran D; Vajdic CM; Zalcberg JR; Gan HK; Gedye C; Varikatt W; Koh E-S; Kichenadasse G; Sim H-W; Gottardo NG; Spyridopoulos D; Jeffree RL, 2021, 'What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry', Neuro-Oncology Practice, http://dx.doi.org/10.1093/nop/npab055

Sim HW; Nowak AK; Lwin Z; Khasraw M, 2021, 'Management of glioblastoma: An Australian perspective', Chinese Clinical Oncology, vol. 10, http://dx.doi.org/10.21037/cco.2020.02.05

Floros P; Rao A; McCloy RA; Sim HW; Chin VT; Leavers BC; Crawford JA; Gallagher RM, 2021, 'Altered presentation of oropharyngeal cancer, a 6-year review', ANZ Journal of Surgery, vol. 91, pp. 1240 - 1245, http://dx.doi.org/10.1111/ans.16537

Kong BY; Carter C; Nowak AK; Hovey E; Lwin Z; Haghighi N; Gan HK; Sim HW; Ziegler DS; Barton K; Parkinson J; Leonard R; Khasraw M; Foote M, 2021, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13606

Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC, 2020, 'Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European urology oncology, vol. 3, pp. 530 - 539, http://dx.doi.org/10.1016/j.euo.2020.01.001

Lamb LS; Sim HW; McCormack AI, 2020, 'Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy', Frontiers in Endocrinology, vol. 11, http://dx.doi.org/10.3389/fendo.2020.576027

Agar M; Nowak A; Hovey E; Barnes E; Simes J; Vardy J; Wheeler H; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim H-W; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh E-S, 2020, 'QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE', Neuro-Oncology, vol. 22, pp. ii179 - ii180, http://dx.doi.org/10.1093/neuonc/noaa215.748

Hallal S; Khani SE; Wei H; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL, 2020, 'Deep sequencing of small RNAs from neurosurgical extracellular vesicles substantiates miR-486-3p as a circulating biomarker that distinguishes glioblastoma from lower-grade astrocytoma patients', International Journal of Molecular Sciences, vol. 21, pp. 1 - 22, http://dx.doi.org/10.3390/ijms21144954

Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R, 2020, 'Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab', Cancer Medicine, vol. 9, pp. 4640 - 4647, http://dx.doi.org/10.1002/cam4.3116

Alghamdi MA; Amaro CP; Lee-Ying R; Sim HW; Samwi H; Chan KK; Knox JJ; Ko YJ; Swiha M; Batuyong E; Romagnino A; Cheung WY; Tam VC, 2020, 'Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database', Cancer Medicine, vol. 9, pp. 4918 - 4928, http://dx.doi.org/10.1002/cam4.3228

Hallal S; Azimi A; Wei H; Ho N; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL, 2020, 'A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: A new avenue for glioma tumour surveillance', International Journal of Molecular Sciences, vol. 21, pp. 1 - 26, http://dx.doi.org/10.3390/ijms21134754

Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim HW; Natori A; Chan BA; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW; Elimova E, 2020, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma', Cancer Medicine, vol. 9, pp. 3023 - 3032, http://dx.doi.org/10.1002/cam4.2948

Ma LX; Espin-Garcia O; Lim CH; Jiang DM; Sim HW; Natori A; Chan BA; Suzuki C; Chen EX; Liu G; Brar SS; Swallow CJ; Yeung JC; Darling GE; Wong RK; Kalimuthu SN; Conner J; Elimova E; Jang RW, 2020, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers', Journal of Gastrointestinal Oncology, vol. 11, pp. 356 - 365, http://dx.doi.org/10.21037/jgo.2020.03.03

Ma LX; Sun P; Espin-Garcia O; Suzuki C; Jiang DM; Lim CH; Taylor K; Chan BA; Sim H-W; Natori A; Chen EX; Liu G; Knox JJ; Yeung J; Darling GE; Kim J; Kalimuthu S; Elimova E; Jang RW-J, 2020, 'Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.', Journal of Clinical Oncology, vol. 38, pp. 328 - 328, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.328

Feng S; Sim H-W; Bucur R; Aggarwal R; Abreu P; Ray M; Herman M; Cheng D; Chen Z; Zhang W; Greig PD; Wei AC-C; Moulton C-A; McGilvray IM; Cleary SP; Gallinger S; Sapisochin G; Knox JJ; Liu G; Chen EX, 2020, 'Preoperative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC).', Journal of Clinical Oncology, vol. 38, pp. 571 - 571, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.571

Hecht JR; Lonardi S; Bendell JC; Sim H-W; Macarulla T; Lopez CD; Van Cutsem E; Martin AJM; Park JO; Greil R; Lin Y; Rao S; Ryoo B-Y, 2020, 'Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).', Journal of Clinical Oncology, vol. 38, pp. 637 - 637, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.637

Lamb LS; Sim HW; McCormack AI, 2020, 'Exploring the role of novel medical therapies for aggressive pituitary tumors: A review of the literature—“are we there yet?”', Cancers, vol. 12, http://dx.doi.org/10.3390/cancers12020308

Kroeger N; Li H; De Velasco G; Donskov F; Sim H-W; Stuehler V; Wells JC; Stukalin I; Heide J; Bedke J; Agarwal N; Parekh H; Rini B; Knox EJ; Pantuck A; Choueiri TK; Heng DYC, 2019, 'Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies', CLINICAL GENITOURINARY CANCER, vol. 17, pp. 65 - 71, http://dx.doi.org/10.1016/j.clgc.2018.09.006

Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2019, 'Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase mutations in gliomas', Clinical Cancer Research, vol. 25, pp. 3366 - 3373, http://dx.doi.org/10.1158/1078-0432.CCR-18-3205

Herman M; Zhang Y; Wang L; Sim H-W; Knox JJ, 2019, 'Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.', JOURNAL OF CLINICAL ONCOLOGY, vol. 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e15645

Khasraw M; Leanne McDonald K; Rosenthal M; Lwin Z; Ashley D; Wheeler H; Barnes E; Foote M; Koh E-S; Sulman E; Back M; Buckland M; Sim H-W; Fisher L; Leonard R; Hall M; Yip S; Simes J, 2019, 'ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY', Neuro-Oncology, vol. 21, pp. vi18 - vi18, http://dx.doi.org/10.1093/neuonc/noz175.067

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', Journal of Clinical Oncology, vol. 37, pp. 4069 - 4069, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4069

Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', Journal of Clinical Oncology, vol. 37, pp. e15579 - e15579, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15579

Jiang DM; Suzuki C; Espin-Garcia O; Pintilie M; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', Journal of Clinical Oncology, vol. 37, pp. 162 - 162, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.162

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', Journal of Clinical Oncology, vol. 37, pp. 164 - 164, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.164

Taylor K; Espin-Garcia O; Jiang DM; Yokom D; Ma LX; Lim CH; Chan BA; Sun P; Sim H-W; Natori A; Liu G; Darling GE; Wong R; Chen EX; Jang RW-J; Veit-Haibach P; Rozenberg D; Elimova E, 2019, 'Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.', Journal of Clinical Oncology, vol. 37, pp. 171 - 171, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.171

Fung AS; Tam VC; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Lee-Ying RM, 2019, 'Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).', Journal of Clinical Oncology, vol. 37, pp. 422 - 422, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.422

Fung AS; Lee-Ying RM; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Tam VC, 2019, 'Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.', Journal of Clinical Oncology, vol. 37, pp. 438 - 438, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.438

Natori A; Chan BA; Sim HW; Ma L; Yokom DW; Chen E; Liu G; Darling G; Swallow C; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox J; Elimova E; Jang RW, 2018, 'Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer', Current Oncology, vol. 25, pp. 366 - 370, http://dx.doi.org/10.3747/co.25.4208

Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2018, 'Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', Cancer, vol. 124, pp. 3677 - 3683, http://dx.doi.org/10.1002/cncr.31595

Sim HW; Knox J, 2018, 'Hepatocellular carcinoma in the era of immunotherapy', Current Problems in Cancer, vol. 42, pp. 40 - 48, http://dx.doi.org/10.1016/j.currproblcancer.2017.10.007

Sim HW; Morgan ER; Mason WP, 2018, 'Contemporary management of high-grade gliomas', CNS oncology, vol. 7, pp. 51 - 65, http://dx.doi.org/10.2217/cns-2017-0026

Mitchell L; Tam S; Lewin J; Srikanthan A; Heck C; Hodgson D; Vakeesan B; Sim HW; Gupta A, 2018, 'Measuring the impact of an adolescent and young adult program on addressing patient care needs', Journal of Adolescent and Young Adult Oncology, vol. 7, pp. 612 - 617, http://dx.doi.org/10.1089/jayao.2018.0015

Samawi HH; Sim HW; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko YJ; Davies JM; Lim HJ; Cheung WY; Tam VC, 2018, 'Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database', Cancer Medicine, vol. 7, pp. 2816 - 2825, http://dx.doi.org/10.1002/cam4.1493

Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA, 2018, 'Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma', International Journal of Cancer, vol. 142, pp. 57 - 65, http://dx.doi.org/10.1002/ijc.31039

Nejad R; Nassiri F; Mamatjan Y; Sim H-W; Chen E; Agnihotri S; Aldape K; Zadeh G, 2018, 'CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS', Neuro-Oncology, vol. 20, pp. vi33 - vi33, http://dx.doi.org/10.1093/neuonc/noy148.125

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang DM; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. 4066 - 4066, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4066

Doherty M; Tam VC; McNamara MG; Hedley DW; Dhani NC; Chen EX; Jang RW-J; Tang PA; Sim H-W; O'Kane GM; DeLuca S; Wang L; Brooks K; Knox JJ, 2018, 'Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.', Journal of Clinical Oncology, vol. 36, pp. 4084 - 4084, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4084

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2 positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. e16069 - e16069, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e16069

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang M; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. 122 - 122, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.122

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 36, pp. 131 - 131, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.131

Ma LX; Lim CH; Sun P; Jiang M; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Le LW; Chen EX; Liu G; Swallow CJ; Darling GE; Kongkham PN; Shultz D; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer.', Journal of Clinical Oncology, vol. 36, pp. 145 - 145, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.145

Jiang DM; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Knox JJ; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Jang RW-J; Elimova E, 2018, 'Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).', Journal of Clinical Oncology, vol. 36, pp. 147 - 147, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.147

Chan BA; Sim H-W; Natori A; Moignard S; Yokom D; Lim CH; Jiang DM; Chen EX; Knox JJ; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Hafezi-Bakhtiari S; Elimova E; Jang RW-J, 2018, 'Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.', Journal of Clinical Oncology, vol. 36, pp. 148 - 148, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.148

Yokom D; Natori A; Sim H-W; Chan BA; Moignard S; Sun P; Lim CH; Jiang DM; Ma LX; Darling GE; Swallow CJ; Brierley JD; Wong R; Liu G; Chen EX; Knox JJ; Alibhai SMH; Jang RW-J; Elimova E, 2018, 'Management of metastatic gastric and esophageal cancer in older adults.', Journal of Clinical Oncology, vol. 36, pp. 163 - 163, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.163

O'Kane GM; Fraser A; Moignard S; Dodd A; Creighton S; Sim H-W; Aung KL; Borgida A; Gallinger S; Knox JJ, 2018, 'The impact of lung and bone metastases on prognosis in advanced PDAC.', Journal of Clinical Oncology, vol. 36, pp. 494 - 494, http://dx.doi.org/10.1200/jco.2018.36.4_suppl.494

Stukalin I; Connor Wells J; Fraccon A; Pasini F; Porta C; Lalani AKA; Srinivas S; Alex Bowman I; Brugarolas J; Lee JL; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim HW; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2018, 'Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)', Kidney Cancer, vol. 2, pp. 31 - 36, http://dx.doi.org/10.3233/KCA-170020

Sim H-W; Stundzia A; Pierre S; Metser U; O’Malley M; Elimova E; Sridhar SS; Hansen A, 2018, 'Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)', Annals of Oncology, vol. 29, pp. viii318 - viii318, http://dx.doi.org/10.1093/annonc/mdy283.105

Meyers DE; Lee-Ying R; Alghamdi M; Sim H-W; Zaborska VO; Ko Y-J; Raycraft T; Batuyong E; Cheung WY; Samawi H; Davies JM; Tam VC, 2018, 'Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database', Annals of Oncology, vol. 29, pp. viii238 - viii238, http://dx.doi.org/10.1093/annonc/mdy282.089

Lalani AKA; Li H; Heng DYC; Wood L; Kalirai A; Bjarnason GA; Sim HW; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa NS, 2017, 'First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience', Journal of the Canadian Urological Association, vol. 11, pp. 112 - 117, http://dx.doi.org/10.5489/cuaj.4398

Sim HW; Knox J; Dawson LA, 2017, 'An Update on Randomized Clinical Trials in Hepatocellular Carcinoma', Surgical Oncology Clinics of North America, vol. 26, pp. 647 - 666, http://dx.doi.org/10.1016/j.soc.2017.05.006

Natori A; Chan BA; Sim H-W; Ma LX; Yokom D; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 35, pp. 10037 - 10037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10037

Sim H-W; Nejad R; Zhang W; Mason WP; Bernstein M; Aldape K; Zadeh G; Chen EX, 2017, 'Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas.', Journal of Clinical Oncology, vol. 35, pp. 2037 - 2037, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2037

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, vol. 35, pp. 3600 - 3600, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3600

Sim H-W; Chan BA; Natori A; Lim CH; Jiang DM; Moignard S; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.', Journal of Clinical Oncology, vol. 35, pp. 4053 - 4053, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4053

Alghamdi MA; Lee-Ying R; Sim H-W; Samawi H; Knox JJ; Romagnino A; Ko Y-J; Chan KK; Swiha M; Batuyong E; Cheung WY; Tam VC, 2017, 'Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.', Journal of Clinical Oncology, vol. 35, pp. 4084 - 4084, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4084

Bosse D; Xie W; Wells C; Lalani A-KA; Donskov F; Bent A; Sim H-W; Beuselinck B; Bamias A; Porta C; Vaishampayan UN; Pal SK; Agarwal N; Srinivas S; Rini BI; Alva AS; Wood L; Kapoor A; Choueiri TK; Heng DYC, 2017, 'Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).', Journal of Clinical Oncology, vol. 35, pp. e16065 - e16065, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16065

Basappa NS; Lalani A-KA; Kalirai A; Li H; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, vol. 35, pp. e16078 - e16078, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16078

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).', Journal of Clinical Oncology, vol. 35, pp. 4580 - 4580, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4580

Samawi H; Sim H-W; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko Y-J; Cheung WY; Tam VC, 2017, 'Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database.', Journal of Clinical Oncology, vol. 35, pp. e15653 - e15653, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15653

Basappa NS; Lalani A-KA; Li H; Kalirai A; Wood L; Kollmannsberger CK; Sim H-W; Kapoor A; Hotte SJ; Czaykowski P; Canil CM; Reaume MN; Bjarnason GA; Vanhuyse M; Soulieres D; Levesque E; North SA; Heng DYC, 2017, 'Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).', Journal of Clinical Oncology, vol. 35, pp. 468 - 468, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.468

Yip S; Wells C; Moreira RB; Wong A; Srinivas S; Beuselinck B; Porta C; Sim H-W; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood L; Soulieres D; Canil CM; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2017, 'Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.', Journal of Clinical Oncology, vol. 35, pp. 492 - 492, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.492

Stukalin I; Wells C; Fraccon AP; Pasini F; Porta C; Moreira RB; Srinivas S; Bowman IA; Brugarolas J; Lee J-L; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim H-W; Agarwal N; Rha SY; Kanesvaran R; Choueiri TK; Heng DYC, 2017, 'Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).', Journal of Clinical Oncology, vol. 35, pp. 498 - 498, http://dx.doi.org/10.1200/jco.2017.35.6_suppl.498

Sim H-W; Chan B; Natori A; Lim CH; Jiang DM; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Jang RW-J; Elimova E, 2017, 'Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 35, pp. 126 - 126, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.126

Natori A; Chan B; Sim H-W; Chen EX; Liu G; Darling GE; Swallow CJ; Brar SS; Brierley JD; Ringash J; Wong R; Kim J-HJ; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox JJ; Elimova E; Jang RW-J, 2017, 'Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, vol. 35, pp. 189 - 189, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.189

Jiang DM; Sim H-W; Siu LL; Shapiro JD; Liu G; Price TJ; Jonker DJ; Karapetis CS; Strickland A; Zhang W; Jeffery M; Tu D; Ng S; Sabesan SS; Shannon J; Townsend AR; Morgen E; Xu W; O'Callaghan CJ; Chen EX, 2017, 'Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, vol. 35, pp. 699 - 699, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.699

Yip SM; Ruiz Morales JM; Donskov F; Fraccon A; Basso U; Rini BI; Lee JL; Bjarnason GA; Sim HW; Beuselinck B; Kanesvaran R; Brugarolas J; Koutsoukos K; Fu SYF; Yuasa T; Davis I; Alva A; Kollmannsberger C; Choueiri TK; Heng DYC, 2017, 'Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)', Kidney Cancer, vol. 1, pp. 41 - 47, http://dx.doi.org/10.3233/KCA-160002

Nejad R; Sim H; Aldape K; Mason W; Bernstein M; Gentili F; Kalia S; Tung T; Chen E; Zadeh G, 2017, 'P10.21 2-hydroxyglutarate as a biomarker for IDH mutation in low grade gliomas', Neuro-Oncology, vol. 19, pp. iii89 - iii90, http://dx.doi.org/10.1093/neuonc/nox036.339

Donskov F; Xie W; Wells JC; Fraccon AP; Pasini F; Porta C; Stukalin I; Lee JL; Bamias A; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim H-W; Agarwal N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC, 2017, 'Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy', Annals of Oncology, vol. 28, pp. v311 - v312, http://dx.doi.org/10.1093/annonc/mdx371.037

Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European Journal of Cancer, vol. 65, pp. 102 - 108, http://dx.doi.org/10.1016/j.ejca.2016.06.016

Chan B; Sim H-W; Zimmermann C; Krzyzanowska MK, 2016, 'Systematic review of interventions to facilitate advance care planning (ACP) in cancer patients.', Journal of Clinical Oncology, vol. 34, pp. 21 - 21, http://dx.doi.org/10.1200/jco.2016.34.26_suppl.21

Sim H-W; Zadeh G; Mason WP; Aldape K; Bernstein M; Gentili F; Hodaie M; Kalia S; Kongkham PN; Zhang W; Tung T; Chen EX, 2016, 'Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues.', Journal of Clinical Oncology, vol. 34, pp. 2028 - 2028, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.2028

Ruiz Morales JM; Swierkowski M; Wells C; Fraccon AP; La Russa F; Donskov F; Bjarnason GA; Lee J-L; Sim H-W; Beuselinck B; Wood L; Yuasa T; Pezaro CJ; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).', Journal of Clinical Oncology, vol. 34, pp. 4510 - 4510, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4510

Li H; Kroeger N; de Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh HD; Rini BI; Knox JJ; Pantuck AJ; Choueiri TK; Heng DYC, 2016, 'The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.', Journal of Clinical Oncology, vol. 34, pp. 552 - 552, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.552

Kröger N; Li H; De Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh H; Rini B; Knox J; Pantuck A; Choueiri T; Heng D, 2016, '756 Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies', European Urology Supplements, vol. 15, pp. e756 - e756, http://dx.doi.org/10.1016/s1569-9056(16)60758-3

Lalani A-K; Li H; Heng D; Wood L; Kalirai A; Bjarnason G; Sim H-W; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa N, 2016, 'Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience', Annals of Oncology, vol. 27, pp. vi285 - vi285, http://dx.doi.org/10.1093/annonc/mdw373.46

Tan LTY; Lewin JH; Urban D; Sim H-W; Hicks RJ; Byron K; Guccione L; Schaef E; Luen SJ; Tothill R; Schofield P; Bowtell D; Mileshkin LR, 2015, 'Retrospective review of the impact of a dedicated Cancer of Unknown Primary (CUP) clinic.', Journal of Clinical Oncology, vol. 33, pp. e17680 - e17680, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e17680

Sim HW; Morris PG; Patil S; Khasraw M, 2014, 'Brain metastases in breast cancer', Expert Review of Anticancer Therapy, vol. 14, pp. 173 - 183, http://dx.doi.org/10.1586/14737140.2014.863468